A randomized split-face clinical trial of conventional vs indoor-daylight photodynamic therapy for the treatment of multiple actinic keratosis of the face and scalp and photoaging. (19th May 2022)

• Record Type: Journal Article
• Authors: Arisi, M.; Rossi, M. T.; Spiazzi, L.; Guasco Pisani, E.; Venturuzzo, A.; Rovati, C.; Tomasi, C.; Venturini, M.; Calzavara-Pinton, P. G.
• Is Part Of: Journal of dermatological treatment. Volume 33:Number 4(2022)
• Page Start: 2250
• Page End: 2256
• Publication Date: 2022-05-19
• Subjects: photodynamic therapy -- actinic keratosis -- photoaging -- split-face -- indoor-daylight -- PDT; Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.1080/09546634.2021.1944594
• Languages: English
• ISSNs: 0954-6634

Abstract

Abstract: Background: Recently, indoor daylight photodynamic therapy (idl-PDT) has been developed; however, its efficacy and tolerability remain to be assessed. Objective: This is a not-inferiority study to compare treatment outcomes of cPDT with a red LED lamp and idlPDT with a polychromatic white LED lamp in adult patients affected by symmetrical AKs of face and/or scalp. Methods: In this comparative, intra-patient, split-face, randomized clinical trial forty-three adult patients were enrolled. Two contralateral and symmetrical target areas of the face and/or scalp harboring at least 5 AKs were selected and randomized 1:1 to treatment with cPDT and idlPDT. The AKs number and cumulative area were assessed at baseline (T0). Efficacy and cosmetic outcome were assessed 3 months after treatment (T1). Results: Total AKs number and area reduced significantly with both idlPDT ( p < .0001) and cPDT ( p < .0001) in comparison to baseline. cPDT was more painful ( p < .0001) and induced a more severe inflammation ( p < .0001). Twenty-nine patients (70.7%) gave their overall preference to idlPDT ( p < .001). Conclusion: idlPDT may represent an alternative treatment protocol to cPDT for in-office treatment of AKs patients with better tolerability and a not inferior efficacy.